George Still (Pediatrician) and Afield Tredgold (Physician) of Britain were the first to document the disease. George Still noted that the diseases primarily presented the inability to follow rules, restlessness, lack of limitation and an over-aroused behavior. He attributed the symptoms to brain trauma, which was strong, associated with genetic or environmental factors. Furthermore, Still described the disease as a defect of cognition, moral consciousness and inhibition violation. He thus named it the deficit of moral control (Batt, 2010). Later on, in 1922, the disease was described in several patients following an influenza epidemic. Majority of the patients developed the disease as a complication of the influenza infection. During this time, the disease was called Encephalitic behavior, which was associated, with brain trauma (Mark, 2007). In 1937, the use of stimulants for the treatment of ADHD was introduced by Dr. Charles Bradley. This significantly improved the outcome of the disease. In 1956, Ritalin (methylphenidate) was considered the drug of choice for patients suffering from the disease. In 1950, various researchers discredited the theory that brain damage resulted in the disease. The disease was then called the Minimal Brain Damage Disorder. It was later referred to as the Minimum Brain Dysfunction disease in 1960 (Mark, 2007). This was because the disease was not associated with other central nervous system deficits. Other symptoms were also associated with the disease, for example, lack of focus. In 1980, a research conducted by Douglas (Psychologist) and others shifted the focus of the disease from behavioral to attention deficit. It was described in the DSM II of the American Psychiatric Association as Attention Deficit Disorder. Later in 1987, it was described in DSM III and DSM IV as Attention Deficit Hyperactivity Disorder. Over the years, the use of stimulant drugs has been applied in the treatment of ADHD (Mark, 2007). In 1999, Focalin and Concerta were used in the treatment of the disease.